You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tace

Showing 1 - 25 of 82
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Patterns of Transcatheter Arterial Chemoembolization Combined

Not yet recruiting
  • HCC
  • TACE
  • (no location specified)
Aug 29, 2023

Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +5 more
  • TACE
  • Tislelizumab, Lenvatinib
  • Hangzhou, Zhejiang, China
    1# Banshan East Rd. Zhejiang cancer hospital
Jun 17, 2023

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone

Completed
  • Hepatocellular Carcinoma
  • TACE-HAIC
  • +3 more
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 8, 2022

Hepatocellular Carcinoma Trial (TACE+Camrelizumab+Apatinib mesylate, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • TACE+Camrelizumab+Apatinib mesylate
  • TACE
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Oct 17, 2022

Hepatocellular Carcinoma Trial in Nanjing (Camrelizumab, TACE, Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Nanjing, Jiangsu, China
    Zhongda Hospital
Sep 8, 2022

Resectable Hepatocellular Carcinoma Trial (Cadonilimab, TACE, Surgery)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Dec 12, 2022

Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,

Recruiting
  • Hepatocellular Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Hepatocellular Carcinoma, TACE, Anlotinib Trial in Lanzhou, Xi'an (Anlotinib Hydrochloride, TACE)

Active, not recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Anlotinib Hydrochloride
  • TACE
  • Lanzhou, Gansu, China
  • +3 more
Jan 12, 2023

Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Feb 7, 2023

Hepatocellular Carcinoma Trial in Shanghai (lenvatinib, TACE)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Huashan hospital
Jul 29, 2022

Carcinoma, Hepatocellular, Hepatic Carcinoma, Hepatocellular Cancer Trial in Hannover (Nivolumab, TACE)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • +2 more
  • Hannover, Germany
    Medizinische Hochschule Hannover, Klinik für Gastroenterologie,
Nov 21, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Oct 20, 2022

Unresectable, Non-metastatic Hepatocellular Carcinoma Trial in China (biological, drug, procedure)

Recruiting
  • Unresectable, Non-metastatic Hepatocellular Carcinoma
  • AK104
  • +2 more
  • Beijing, Beijing, China
  • +4 more
Aug 11, 2022

Hepatocellular Carcinoma Trial in Shanghai (Sintilimab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
May 30, 2022

HCC Trial in Hong Kong (procedure, radiation, drug)

Active, not recruiting
  • HCC
  • TACE
  • +2 more
  • Hong Kong, Hong Kong
    Department of Clinical Oncology
Oct 24, 2022

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

Carcinoma, Hepatocellular Trial in Navi Mumbai (radiation, procedure, drug)

Recruiting
  • Carcinoma, Hepatocellular
  • SBRT
  • +2 more
  • Navi Mumbai, Maharashtra, India
  • +1 more
Apr 25, 2022

Advanced Hepatocellular Carcinoma Trial in Hangzhou (Envafolimab, TACE, Lenvatinib)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Hangzhou, Zhejiang, China
    the First Affiliated Hospital, School of Medicine, Zhejiang Univ
Mar 13, 2022

Donafenib Trial in Shanghai (Donafenib, PD-1, TACE)

Recruiting
  • Donafenib
  • Donafenib, PD-1
  • TACE
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University,
Mar 4, 2022

Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization, Regorafenib Trial in Guangzhou (TACE, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    FirstSunYetSen
Apr 12, 2023

Hepatocellular Carcinoma Trial in Beijing (HAIC, TACE, FOLFOX)

Recruiting
  • Hepatocellular Carcinoma
  • HAIC
  • +4 more
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jan 10, 2022

Hepatocellular Carcinoma Trial (Donafenib, TACE)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Oct 8, 2022

Hepatocellular Carcinoma Trial in New York (SBRT, TACE)

Completed
  • Hepatocellular Carcinoma
  • SBRT
  • TACE
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Nov 22, 2022